ING Groep NV Acquires Shares of 19,800 Repligen Corporation $RGEN

ING Groep NV acquired a new stake in Repligen Corporation (NASDAQ:RGEN) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 19,800 shares of the biotechnology company’s stock, valued at approximately $3,244,000.

Other institutional investors have also recently bought and sold shares of the company. Measured Wealth Private Client Group LLC bought a new position in Repligen in the 3rd quarter valued at $29,000. Bayforest Capital Ltd bought a new position in Repligen in the 4th quarter valued at $32,000. Rachor Investment Advisory Services LLC bought a new position in Repligen in the 4th quarter valued at $33,000. Los Angeles Capital Management LLC bought a new position in Repligen in the 4th quarter valued at $36,000. Finally, Farther Finance Advisors LLC raised its position in Repligen by 61.8% in the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 128 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Up 2.5%

NASDAQ RGEN opened at $125.33 on Tuesday. The stock has a fifty day moving average of $118.88 and a 200-day moving average of $138.50. The stock has a market capitalization of $7.07 billion, a P/E ratio of 139.26, a price-to-earnings-growth ratio of 2.36 and a beta of 1.09. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $175.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The company had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same period last year, the firm earned $0.39 EPS. The business’s revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, equities research analysts forecast that Repligen Corporation will post 1.99 EPS for the current year.

Wall Street Analyst Weigh In

RGEN has been the subject of several research analyst reports. HSBC cut their price objective on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. HC Wainwright lifted their target price on Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, March 23rd. Rothschild & Co Redburn set a $160.00 target price on Repligen and gave the company a “buy” rating in a research note on Friday, April 17th. Weiss Ratings raised Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, May 7th. Finally, Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $164.64.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.